190 Everett Ave.

Acorda Therapeutics, a biotechnology company that develops and commercializes neurology therapies, wanted to expand its Everett site to accommodate its newly approved drug manufacturing. The FDA had recently granted approval on their new drug INBRIJA, a levodopa inhalation powder, which gives patients with Parkinson’s relief through an inhaler rather than a pill. Their proposed year to start the drug manufacture was 2019, and one hundred new jobs were created along with this expansion.

TG Gallagher was appointed to work with Skanska on this PID project.  Despite not having a finalized floor plan, TG Gallagher strategically placed the piping to ensure a smooth process going forward.  The project included the installation of several systems: 3 glycol systems (Chilled, tempered and jacketed), 4 steam systems, 4 gas systems (compressed air, nitrogen, ethanol and clean dry air), syltherm, solvent waste and vacuums. A new technique applied by TG Gallagher was the prefabrication of the bed floor stands for VAV piping trim. This enabled installation of the vertical duct above the finished floor serving the room directly below.  Piping headers, AHU coil trims, a water heater skid, and SS acid waste piping were also prefabricated. In order to successfully meet Acorda’s strict deadline, TG Gallagher strategically deployed its workforce to maximize manpower.

Architect: CRB
Engineer: CRB
General Contractor: Skanska